Paul McInulty is Senior Vice President, Regulatory Affairs at Arvinas. Mr. McInulty has over 25 years of experience in both small and large pharmaceutical companies leading all aspects of regulatory affairs with significant clinical regulatory strategy leadership expertise. Mr. McInulty joined Arvinas after serving as Vice President, Therapeutic Head, Hematology and Precision Medicines Regulatory Affairs at Bristol Myers Squibb where he led a regulatory team responsible for hematology indications and precision medicine and drove the regulatory strategy and implementation of activities needed to secure approval of new drugs and expanded indications across the hematology product portfolio.
Previously, Mr. McInulty spent 15 years at Celgene Corporation in various roles of increasing responsibility including serving as Vice President, Regulatory Affairs, Hematology/Oncology where he led the regulatory team responsible for Hematology/Oncology Indications, including all cell therapy programs.
Mr. McInulty received his B.Sc. in Pharmacology from the University of Sheffield, Department of Pharmacology.